Investors

Investors: Capture New, Unaddressed Market Opportunities

60° Pharmaceuticals (60P): A two-pronged mission for investors

  •       Commitment to developing new therapies for the treatment and prevention of tropical diseases
  •       Privately held company that is interested in a healthy return on investment

Investing in an established market

A tremendous investment opportunity exists due to the ineffective preventative malaria therapies currently on the market along with expanding disease risks. This calls for more effective and efficient prevention therapies.

60P: Exclusive rights to develop Tafenoquine (for malaria prevention)

  • Secured research and licensing agreements, sponsorships rights, and use patents with the U.S. Army
  • Ongoing U.S. Army-support $US18+ million for development program

Competitive advantages in dengue fever treatment

  • Celgosivir and Modipafant: Decreasing disease burden
    • Targeted usage will be to prevent or reduce the incidence and duration of illness and/or disease severity
    • Fills treatment void: Currently no effective therapeutic products against dengue
  • 60P: Significant clinical development achievements
    • Phase IB study has been completed on Celgosivir (60P001)
    • Regulatory/ethical approval in Singapore to conduct Phase II study
    • Singapore government-supported US$3.7 million grant

The experience to succeed

Founded by industry veterans, 60P has leadership with over 80 years of combined pharmaceutical business experience—including new product development, product management, regulatory approval, and marketing.

60P Collaboration Partners

U.S. Army

  • 60P’s Malaria Program attracted a high level of interest from the U.S. Army Medical and Materiel Development Activity (USAMMDA), as malaria is currently identified by Department of Defense as the number one infectious disease threat to its global activities
  • Manages its research grants through the USAMMDA Pharmaceutical Systems Department, whose mission is to serve as the Army’s premier extramural basic research agency and strengthen the academic, industrial, and nonprofit laboratory research infrastructure servicing the Army

 

Knight Therapeutics

  • Specialty pharmaceuticals company focused on acquiring or in-licensing innovative pharmaceutical products for Canadian market and other select international markets
  • Multiple tranches of funding provided for the 60P malaria program totaling US $5.0 million

Innovation and product development

To innovate new tropical disease treatments, 60P collaborates with other public and private entities to proceed collectively.

A partnership built on trust and efficiency

As 60P continues to achieve significant clinical development milestones, the expansion arising out of investment will enable 60P to accelerate its path to market. Ideally, 60P seeks to augment its experience in development, manufacturing, and commercialization of drugs.

Operations

Headquarters: Washington, D.C. (USA)

Research and Development: Australia & Singapore

History

  • 2010: 60P established
  • 2012: Secured $2 million in initial funding
  • 2013: Established an Australian subsidiary to support global research projects
  • 2014: Commercialization of tafenoquine for malaria prophylaxis initiated with U.S. Army
  • 2015: The Singapore Ministry of Health (MOH) provided regulatory approval and $4 million in financial support to conduct a Phase II dengue study
  • 2016: Knight Pharmaceuticals provided $4 million in financing to support the 60P tafenoquine program
  • 2017: 60P filed IND for tafenoquine with a target indication for the prevention of malaria
FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial guidance, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “targets,” “forecasts,” “estimates” and similar expressions in conjunction with, among other things obtaining future product sales, discussions of the Company’s outlook, financial performance or financial condition, growth strategy, government development or procurement contracts or awards, government appropriations, manufacturing capabilities, product development, or regulatory approvals or expenditures and plans to increase our operational efficiencies and cost structure are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
429,000

Deaths annually in endemic countries from malaria

125,000,000

Travelers to endemic regions per annum

390,000,000

Dengue infections per year

202-327-5422

1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036